Detalhe da pesquisa
1.
Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.
Nucleic Acids Res
; 50(1): 333-349, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928377
2.
SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
Vaccines (Basel)
; 12(3)2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38543942
3.
Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients.
Front Immunol
; 14: 1172477, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37063863
4.
Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients.
Clin Kidney J
; 16(12): 2447-2460, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38046025
5.
Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage.
Nat Commun
; 14(1): 4564, 2023 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507393
6.
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing.
Comput Struct Biotechnol J
; 20: 799-811, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35126884
7.
Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients.
Vaccines (Basel)
; 10(8)2022 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36016216
8.
Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes.
J Control Release
; 345: 661-674, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35364120
9.
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.
Nat Commun
; 13(1): 153, 2022 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35013191
10.
Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
EBioMedicine
; 85: 104294, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206622
11.
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
Nat Med
; 28(3): 496-503, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35090165
12.
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
Antiviral Res
; 196: 105197, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774603